OSE Immunotherapeutics jumps on U.S. first notice of allowance for antibody for cancer treatment

Ose Immunotherapeutics SA

22/03/2022 08:47

** Shares in OSE Immunotherapeutics  OSE.PA  soar more than
11% after the U.S. Patent And Trademark Office (USPTO) issued a
first notice of allowance for the company's patent application
on OSE-279 antibody to treat cancer  urn:newsml:reuters.com:*:nASM0004DY
    ** "We look forward advancing our anti-PD1 backbone
development with Phase 1 clinical trial planned to start in
2022," the biotechnology group's CEO said
    ** The patent will strengthen the global intellectual
property of OSE-279 and provide the product a protection until
2039
    ** All seven analysts covering the stock rate it "strong
buy" or "buy"​



 (Reporting by Olivier Cherfan)
 ((olivier.cherfan@thomsonreuters.com))